Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
10.11
-0.07 (-0.69%)
Nov 22, 2024, 4:00 PM EST - Market closed
Mesoblast Revenue
In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M, down -21.32%. Mesoblast had revenue of $1.26M in the quarter ending June 30, 2024, a decrease of -41.23%.
Revenue (ttm)
$5.90M
Revenue Growth
-21.32%
P/S Ratio
n/a
Revenue / Employee
$80,849
Employees
73
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Brookdale Senior Living | 2.95B |
| Aveanna Healthcare Holdings | 1.98B |
| OPKO Health | 711.41M |
| ANI Pharmaceuticals | 555.46M |
| Phreesia | 389.96M |
| Artivion | 384.90M |
| Avadel Pharmaceuticals | 138.16M |
| Applied Therapeutics | -212.00K |
MESO News
- 23 days ago - Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 - GlobeNewsWire
- 7 weeks ago - Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential - Seeking Alpha
- 7 weeks ago - Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch - GlobeNewsWire
- 3 months ago - Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 - GlobeNewsWire
- 3 months ago - Mesoblast Financial Results and Corporate Update Webcast - GlobeNewsWire
- 4 months ago - Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 - GlobeNewsWire
- 4 months ago - FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) - GlobeNewsWire